课题基金 / 基金详情

BLOOD PROGENITOR CELL MOBILIZATION BY R-METHUSCF & R-METHUG-CSF IN BREAST CANCER

BLOOD PROGENITOR CELL MOBILIZATION BY R-METHUSCF & R-METHUG-CSF IN BREAST CANCER
R-METHUSCF 动员血液祖细胞
批准号：
6244976
负责人：
Thomas C. Shea
金额：
$1.34万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-06 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244976
关键词：
CD34 molecule antineoplastics breast neoplasms clinical research clinical trials colony stimulating factor combination cancer therapy dosage hematopoietic growth factor human subject human therapy evaluation intracellular transport metastasis neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy neutrophil platelets recombinant proteins

项目摘要

项目成果

Thomas C. Shea的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To compare the number of aphereses required to harvest at least 5 x 10-6 CD34+ cells/kg actual body weight, using either r-metHUSCF in combination with Filgra-stim or Filigrastim alone for mobilization or progenitor cells in patients with high risk Stage II, Stage III or Stage IV breast cancer. To demonstrate equivalent engraftment, as assessed by recovery of neutophils and platelets, PBPC mobilized by either r-metHUSCF plus Filigrastim or Filgrastim alone when used as cellular support post high dose chemotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
海外基金